Research map: Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines
Back to the article
Papers in this map
Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends
· Moien AB Khan · 2019 · 3247 citations · Cited by this paper
Relationships among nitrous oxide exposure, neurological injury and biomarkers
· 2026 · Related
Determinants of patient adherence: a review of systematic reviews
· Przemysław Kardas · 2013 · 817 citations · Cited by this paper
Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers
· 2026 · Related
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
· Lorraine Lucille Lipscombe · 2018 · 247 citations · Cited by this paper
Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study
· 2026 · Related
The European Medicines Agency's approval of new medicines for type 2 diabetes
· EBERHARD BLIND · 2018 · 36 citations · Cited by this paper
Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
· 2026 · Related
Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study
· Britney A. Stottlemyer · 2023 · 34 citations · Cited by this paper
MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)
· 2026 · Related
Initial Combination Therapy in Type 2 Diabetes
· Ji Yoon Kim · 2023 · 26 citations · Cited by this paper
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
· 2026 · Related
The Marginal Costs of Adverse Drug Events Associated With Exposures to Anticoagulants and Hypoglycemic Agents During Hospitalization
· William D. Spector · 2017 · 22 citations · Cited by this paper
Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025
· 2026 · Related
National Action Plan for Adverse Drug Event Prevention: Recommendations for Safer Outpatient Opioid Use
· Aaron Rich Ducoffe · 2016 · 18 citations · Cited by this paper
Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System
· 2026 · Related
Assessment of suspected adverse drug reactions in elderly patients with diabetes mellitus based on a Portuguese spontaneous reporting database: analysis of reporting from 2008 to 2018
· Cristina Sofia de Jesus Monteiro · 2021 · 8 citations · Cited by this paper
A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience
· 2026 · Related
Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF‐α Inhibitors
· Lotte A. Minnema · 2020 · 7 citations · Cited by this paper
Perceptions of prescribing violations by doctors: A qualitative study using semi‐structured interviews
· 2026 · Related
Approved and Commercialized Antidiabetic Medicines (Excluding Insulin) in Seven European Countries—A Cross-Sectional Comparison
· Ana-Maria Atănăsoie · 2024 · 4 citations · Cited by this paper
The Prescription and Safety of Oral Antidiabetic Drugs in Outpatients with Type 2 Diabetes Mellitus: An Observational, Retrospective, Multicenter Study on the Role of Adherence in a Real-Life Primary Care Setting
· Gianmarco Marcianò · 2024 · 3 citations · Cited by this paper
»Ich fürchte, das kann ich in Europa nicht erklären«
· Deborah Benjamin Kaufmann · 2025 · 2 citations · Cited by this paper
Adverse Drugs Reaction and Prescribing Pattern of Antidiabetic Medications in Type 2 Diabetes Patients: An Observational Ambispective Study
· S. K. Prajapati · 2024 · 1 citation · Cited by this paper
Source: OpenAlex (CC0)